CIK 0001936258 · Large accelerated filer
NewAmsterdam Pharma Co N.V.
Sign in to watch- Ticker
- NAMS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Netherlands
- Entity type
- operating
- Phone
- 35 206 2971
- Business address
- GOOIMEER 2-35, NARRDEN, Netherlands, 1411 DC
- Former names
- NewAmsterdam Pharma Co B.V.
Securities
- NAMS Ordinary Shares Nasdaq
- NAMSW Warrant Nasdaq
- Open-market buys, last 90 days
- $226,500
- in 1 filing
- Open-market sales, last 90 days
- $4,661,919
- in 3 filings, $4.6M under 10b5-1 plans
Net −$4,435,419. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-09-26 | Audet Juliette Berangere Chief Business Officer | Purchase | +1,104 | $15.70 | $17K | 1,104 |
| 2024-08-20 | Davidson Michael H. Chief Executive Officer | Purchase | +5,000 | $16.27 | $81K | 209,784 |
| 2024-07-17 | McKenna Mark C. Director | Grant or award · Option (right to buy) | +72,500 | 72,500 | ||
| 2024-06-20 | Davidson Michael H. Chief Executive Officer | Purchase | +5,000 | $17.26 | $86K | 204,784 |
| 2024-04-01 | Audet Juliette Berangere Chief Business Officer | Grant or award · Option (right to buy) | +250,000 | 250,000 | ||
| 2024-03-26 | Topper James N Director | Purchase | +8,429 | $21.50 | $181K | 3,008,429 |
| 2024-03-26 | Kastelein Johannes Jacob Pieter Chief Scientific Officer | Option exercise | +201,673 | 201,673 | ||
| 2024-03-26 | Kastelein Johannes Jacob Pieter Chief Scientific Officer | Shares withheld for taxes | −11,197 | $22.72 | $254K | 190,476 |
| 2024-03-26 | Kastelein Johannes Jacob Pieter Chief Scientific Officer | Sale | −190,476 | $21.50 | $4.1M | 0 |
| 2024-03-26 | Kastelein Johannes Jacob Pieter Chief Scientific Officer | Option exercise · Option (right to buy) | −201,673 | 970,229 | ||
| 2024-02-13 | LANGE LOUIS G Director | Purchase | +5,000 | $19.00 | $95K | 24,878 |
| 2024-01-04 | Lewis William Director | Grant or award · Option (right to buy) | +100,000 | 100,000 | ||
| 2024-01-01 | Kooij Louise Frederika Chief Accounting Officer | Grant or award · Option (right to buy) | +150,494 | 150,494 | ||
| 2024-01-01 | Kling Douglas F Chief Operating Officer | Grant or award · Option (right to buy) | +323,771 | 323,771 | ||
| 2024-01-01 | van der Kamp Hilde Johanna Director | Grant or award · Option (right to buy) | +10,000 | 10,000 | ||
| 2024-01-01 | LANGE LOUIS G Director | Grant or award · Option (right to buy) | +10,000 | 10,000 | ||
| 2024-01-01 | Kastelein Johannes Jacob Pieter Chief Scientific Officer | Grant or award · Option (right to buy) | +500,000 | 500,000 | ||
| 2024-01-01 | Davidson Michael H. Chief Executive Officer | Grant or award · Option (right to buy) | +1,039,939 | 1,039,939 | ||
| 2024-01-01 | Smither John W Director | Grant or award · Option (right to buy) | +10,000 | 10,000 | ||
| 2024-01-01 | Somaiya Mayur Ian Chief Financial Officer | Grant or award · Option (right to buy) | +80,000 | 80,000 |
Page 15 of 15 · 300 trades